Phillips Andrew John 4
4 · MoonLake Immunotherapeutics · Filed May 5, 2022
Insider Transaction Report
Form 4
Phillips Andrew John
Director
Transactions
- Award
Option to Buy
2022-04-06+45,000→ 45,000 totalExercise: $12.25Exp: 2032-04-06→ Class A ordinary shares, par value $0.0001 per share (45,000 underlying)
Footnotes (1)
- [F1]Dr. Phillips was granted 45,000 options on April 6, 2022 pursuant to the MoonLake Immunotherapeutics 2022 Equity Incentive Plan (the "Plan"), vesting one-third on each of April 6, 2023, April 6, 2024 and April 6, 2025, in each case, subject to the terms of the Plan. Each option represents the right to acquire one Class A ordinary share, par value $0.0001 per share, of the Issuer.